May Melissa, Mehboob Shahila, Mulhearn Debbie C, Wang Zhiqiang, Yu Huidong, Thatcher Gregory R J, Santarsiero Bernard D, Johnson Michael E, Mesecar Andrew D
Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, Chicago, IL 60607, USA.
J Mol Biol. 2007 Aug 31;371(5):1219-37. doi: 10.1016/j.jmb.2007.05.093. Epub 2007 Jun 4.
Glutamate racemase (RacE) is responsible for converting l-glutamate to d-glutamate, which is an essential component of peptidoglycan biosynthesis, and the primary constituent of the poly-gamma-d-glutamate capsule of the pathogen Bacillus anthracis. RacE enzymes are essential for bacterial growth and lack a human homolog, making them attractive targets for the design and development of antibacterial therapeutics. We have cloned, expressed and purified the two glutamate racemase isozymes, RacE1 and RacE2, from the B. anthracis genome. Through a series of steady-state kinetic studies, and based upon the ability of both RacE1 and RacE2 to catalyze the rapid formation of d-glutamate, we have determined that RacE1 and RacE2 are bona fide isozymes. The X-ray structures of B. anthracis RacE1 and RacE2, in complex with d-glutamate, were determined to resolutions of 1.75 A and 2.0 A. Both enzymes are dimers with monomers arranged in a "tail-to-tail" orientation, similar to the B. subtilis RacE structure, but differing substantially from the Aquifex pyrophilus RacE structure. The differences in quaternary structures produce differences in the active sites of racemases among the various species, which has important implications for structure-based, inhibitor design efforts within this class of enzymes. We found a Val to Ala variance at the entrance of the active site between RacE1 and RacE2, which results in the active site entrance being less sterically hindered for RacE1. Using a series of inhibitors, we show that this variance results in differences in the inhibitory activity against the two isozymes and suggest a strategy for structure-based inhibitor design to obtain broad-spectrum inhibitors for glutamate racemases.
谷氨酸消旋酶(RacE)负责将L-谷氨酸转化为D-谷氨酸,D-谷氨酸是肽聚糖生物合成的重要组成部分,也是病原体炭疽芽孢杆菌多聚-γ-D-谷氨酸荚膜的主要成分。RacE酶对细菌生长至关重要,且缺乏人类同源物,这使其成为抗菌治疗药物设计与开发的有吸引力靶点。我们已从炭疽芽孢杆菌基因组中克隆、表达并纯化了两种谷氨酸消旋酶同工酶RacE1和RacE2。通过一系列稳态动力学研究,并基于RacE1和RacE2均能催化快速形成D-谷氨酸的能力,我们确定RacE1和RacE2是真正的同工酶。测定了与D-谷氨酸结合的炭疽芽孢杆菌RacE1和RacE2的X射线结构,分辨率分别为1.75 Å 和2.0 Å。两种酶均为二聚体,单体以“尾对尾”方向排列,类似于枯草芽孢杆菌RacE结构,但与嗜热栖热菌RacE结构有很大不同。四级结构的差异导致不同物种间消旋酶活性位点的差异,这对这类酶基于结构的抑制剂设计工作具有重要意义。我们发现RacE1和RacE2活性位点入口处存在缬氨酸到丙氨酸的变异,这使得RacE1的活性位点入口空间位阻较小。使用一系列抑制剂,我们表明这种变异导致对两种同工酶的抑制活性存在差异,并提出了一种基于结构的抑制剂设计策略,以获得谷氨酸消旋酶的广谱抑制剂。